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Abstract
The Takotsubo syndrome (TTS) is a transient cardiac dysfunction characterised by a 
variety of ventricular wall-motion abnormalities. Alternative nomenclatures for this dis-
order include stress-induced cardiomyopathy, apical ballooning syndrome and ‘broken 
heart syndrome’. TTS bears stark resemblance to an acute coronary syndrome, wherein 
patients present with acute chest pain and initial diagnostic workup correlates to abnor-
malities suggesting significant coronary stenosis. Interestingly, the distinguishing factor 
in TTS is the absence of an occlusive coronary vascular disease, which could correlate 
with these changes. The underlying pathophysiology explaining the evolution of TTS 
is still debatable; however, results from various recent studies and registers have shed 
more light on this obscure clinical entity. The detailed description of a criterion which 
demonstrably includes most patients with probable TTS has helped tune management 
strategies in ensuring necessary supportive care and early therapeutic interventions of 
complications, which could arise in course of the disease.
Keywords: Takotsubo cardiomyopathy, pathophysiology, catecholamines, 
complication, diagnosis, treatment
1. Introduction
The Takotsubo syndrome (TTS), first described in 1990 by Sato et al., is a transient cardiac dys-
function characterised by a variety of ventricular wall-motion abnormalities [1, 2]. Its name 
is derived from the resemblance of the left ventricle at end-systole to the octopus-pots of 
Japanese fishermen in the Hiroshima fish markets [3]; however, alternative nomenclatures 
such as stress or stress-induced cardiomyopathy, apical ballooning syndrome and ‘broken 
heart syndrome’ have also been used to label this usually reversible form of acute heart failure 
[4–7]. This clinical entity essentially mimics an acute coronary syndrome, wherein patients 
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present with acute chest pain, and demonstrates the typical biomarker profile (release of 
cardiac troponin and creatine kinase) and/or electrocardiographic abnormalities suggesting 
significant coronary stenosis. Interestingly, the distinguishing factor in Takotsubo syndrome 
is the absence of an occlusive coronary vascular disease, which correlates with these changes 
[8]. Although, the pathophysiology of this disorder remains unclear, recent hypotheses have 
suggested a form of acute catecholaminergic myocardial stunning to explain the pattern of 
temporary LV dysfunction and regional wall-motion abnormality commonly seen at the time 
of presentation [9].
2. Definition
The Takotsubo syndrome is an acute and usually reversible form of heart failure, precipi-
tated by physical and/or emotional stresses or in some cases without any evident preced-
ing trigger. In recent years, various institutions and working groups such as the Mayo 
Clinic, the Gothenburg group, the Japanese Circulation Society and the Takotsubo Italian 
Network have proposed their diagnostic criteria to better define this disease; however, in 
2015, the Heart Failure Association for the European Society of Cardiology (HFA) outlined 
its conclusive version. This has been outlined in Table 1 [8, 10]. A significant feature of this 
criterion is the inclusion of pheochromocytoma as a trigger for this syndrome. Patients 
diagnosed with this disorder could suffer from an acute Takotsubo syndrome in the event 
of a catecholamine storm, analogous to the response incited by other emotional or physical 
stresses.
• Transient regional wall-motion abnormalities of LV or RV myocardium which are frequently, but not always, 
preceded by a stressful trigger (emotional or physical).
• The regional wall-motion abnormalities usuallya extend beyond a single epicardial vascular distribution, and 
often result in circumferential dysfunction of the ventricular segments involved.
• The absence of culprit atherosclerotic coronary artery disease including acute plaque rupture, thrombus forma-
tion, and coronary dissection or other pathological conditions to explain the pattern of temporary LV dysfunction 
observed (e.g. hypertrophic cardiomyopathy, viral myocarditis).
• New and reversible electrocardiography (ECG) abnormalities (ST-segment elevation, ST depression, LBBB,b 
T-wave inversion, and/or QTc prolongation) during the acute phase (3 months).
• Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during the acute phase.
• Positive but relatively small elevation in cardiac troponin measured with a conventional assay (i.e. disparity 
between the troponin level and the amount of dysfunctional myocardium present).c
• Recovery of ventricular systolic function on cardiac imaging at follow-up (3–6 months).d
aAcute, reversible dysfunction of a single coronary territory has been reported.
bLeft bundle branch block may be permanent after Takotsubo syndrome, but should also alert clinicians to exclude other 
cardiomyopathies. T-wave changes and QTc prolongation may take many weeks to months to normalise after recovery 
of LV function.
cTroponin-negative cases have been reported, but are atypical.
dSmall apical infarcts have been reported. Bystander sub-endocardial infarcts have been reported, involving a small 
proportion of the acutely dysfunctional myocardium. These infarcts are insufficient to explain the acute regional wall-
motion abnormality observed.
Table 1. Heart Failure Association diagnostic criteria for Takotsubo syndrome [10].
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3. Clinical subtypes: the primary and secondary Takotsubo syndrome
An attempt to classify Takotsubo patients based on the evolving clinical scenario has helped 
outline two elemental subtypes. The primary form of the syndrome includes patients devel-
oping acute cardiac symptoms, possibly in the wake of a stressful trigger, as also those whose 
co-morbid conditions act as predisposing factors indirectly contributing to rising levels of 
catecholamines. The secondary form comprises patients, wherein the result is essentially a 
response to either a primary medical condition or treatment, and the pathophysiological pro-
cess is probably mediated by a sudden activation of the sympathetic nervous system or at 
times by an increased catecholamine activity [11]. Some examples of triggers for the second-
ary Takotsubo syndrome include acute neuromuscular crises, especially if involving acute 
respiratory failure (acute myasthenia gravis, acute Guillain-Barre syndrome), attempted 
suicide, severe sepsis, infection, babesiosis, pacemaker implantation, electrical DC conver-
sion for atrial fibrillation, acute pulmonary embolism, acute pneumothorax, pheochromocy-
toma, Addisonian crisis, hyperglycaemic hyperosmolar state, blood transfusions, thrombotic 
thrombocytopenic purpura, acute exacerbation of asthma or COPD, induction of general 
anaesthesia, cocaine abuse, acute cholecystitis, acute pancreatitis, surgery, dobutamine stress 
echocardiography, etc.
4. Anatomical variants
A study describing the varying morphological presentations of the left ventricle in patients 
diagnosed with the Takotsubo syndrome has led to the identification of at least four major 
anatomical variants [12, 13]. The classical pattern defined by an apical ballooning of the left 
ventricle at end-systole is present in at least 50–80% of the cases. The inverted Takotsubo 
(basal) variant with a predominantly hypokinetic circumferential base; the mid left ven-
tricular variant with a hypokinetic circumferential mid ventricle; and the focal variant 
constitute other forms of presentation. Rarer variations include cases with a pronounced 
dysfunction of the biventricular apex and those with an isolated right ventricular involve-
ment [14–16].
5. Epidemiology
A retrospective review of studies reporting cases of the Takotsubo syndrome has estimated 
that these patients account for approximately 2% of all suspected cases of an acute coronary 
syndrome [17]. The average age of the TTS patient at presentation was around 68 years 
and the gender bias skewed to a female preponderance for disease, with 90% of the diag-
nosed population constituting postmenopausal women. The Nationwide Inpatient Sample 
Database (NIS-USA) reported that 24,701 patients were diagnosed with the Takotsubo syn-
drome between 2008 and 2009 in the United States, and an extrapolation of this data sug-
gests that there could be as many as 50,000–100,000 cases per annum in the United States 
alone [11].
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6. Pathophysiology
There have been several hypotheses postulated in contemporary literature, insinuating 
the complex pathophysiological evolution of the Takotsubo syndrome from either pos-
sible coronary microvascular dysfunction, coronary artery spasm, catecholamine-induced 
myocardial stunning, acute left ventricular outflow obstruction, acute increased ventricular 
afterload, myocardial microinfarction or abnormalities in cardiac fatty acid metabolism [10]. 
The potential for excessive hypothalamic-pituitary-adrenal axis (HPA) gain and epinephrine 
release in the event of a stressful trigger, and the corresponding response of the cardiovas-
cular system and the sympathetic nervous system to the following surge in levels of cat-
echolamines is the driving theory currently attributed to the pathophysiological evolution 
of TTS [10, 18].
The consistent presence of microvascular dysfunction in TTS patients has been effectively 
elucidated in the studies by Uchida et al. (report of extensive endothelial cell apoptosis on 
myocardial biopsy) and Afonso et al. (demonstrated circulatory disturbance on myocardial 
contrast echocardiography). A detailed study describing coronary microvascular dysfunction 
in patients diagnosed with the Takotsubo syndrome suggested abnormalities consistent with 
endothelium-dependent vasodilation, excessive vasoconstriction and impairment of myocar-
dial perfusion [19]. Additionally, myocardial biopsy of these patients showed regions with 
contraction band necrosis, inflammatory cell infiltration and localised fibrosis [20]. These 
changes have been attributed to direct catecholamine toxicity on cardiac muscle cells [21]. 
Kurisu et al. demonstrated using the TIMI frame count method, which impaired coronary 
blood flow corresponding to LV wall-motion abnormalities immediately after onset of TTS 
and improved on the resolution of the LV dysfunction, giving credence to the theory of coro-
nary microvascular impairment.
In another study, Morel et al. suggested that an increase in C-reactive protein levels and 
white blood cell counts corresponded to increased levels of catecholamines in TTS patients 
[22]. The possible role of systemic inflammation mediated by catecholamine-induced pro-
inflammatory cytokines like TNF-alpha and interleukin-6 has been used to explain the 
myocardial oedema observed in cardiac MRI [23].
Recent studies conducted by Wittstein et al. (proving catecholamine levels are two to three 
times greater in patients with TTS as compared to those with myocardial infarction) and 
Lyon et al. (proposing ‘stimulus trafficking’ as the cause of decline of myocyte contractile 
function in TTS patients) give support to the theory that catecholamine-induced cardio-
toxicity plays a significant role in the development of the Takotsubo syndrome [17]. It is 
currently hypothesised that the pathophysiology of TTS could be dictated by changes in 
beta-adrenergic receptor (AR) signalling [24–26]. A switch in intracellular signal trafficking 
from Gs protein to Gi protein (signalling through the β2AR) mediates a negative inotro-
pic effect, greatest at the apical myocardium where the density of β-adrenoceptors is the 
highest. This mechanism of stimulus trafficking is triggered by excessively high levels of 
catecholamines and has been used to explain the acute apical cardio-depression in TTS [26].
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7. Risk factors
Lack of oestrogen has often been cited as a risk factor contributing to the development of 
TTS. The preponderance of postmenopausal women affected by this syndrome has led to 
studies investigating the use of hormone replacement theory among these patients. One such 
study by Kuo et al., although constituting a small sample size, showed that none of their TTS 
patients received any form of oestrogen replacement [27]. Recent work by Ueyema et al. in 
ovariectomised rats subjected to stress showed that decrease in LV function was more pro-
nounced in those receiving estradiol supplements [28].
Patients with mood disorders and those using antidepressants tend to have an increased 
risk of developing TTS [29]. There is also an attempt to identify genetic factors that could 
suggest susceptibility to this syndrome. Although adrenoceptor polymorphisms are yet 
to be identified, patients with TTS have been shown to have a L41Q polymorphism of G 
protein coupled receptor kinase (GRK5) more frequently as compared to the normal popu-
lation [30].
8. Clinical features of the Takotsubo syndrome
The definitive patient with a primary Takotsubo syndrome would be represented by a post-
menopausal woman with experience of an acute, unexpected emotional or physical stress 
[31]. This bias, however, does not preclude men, younger women and patients with no iden-
tifiable trigger from a possible TTS. Consequently, gender, menopausal status and stressful 
triggers are not mandatory features included in the HFA criteria.
Patients typically present with acute chest pain are consistent with symptoms of angina pec-
toris, dyspnoea and palpitations. Pre-syncope and syncope due to ventricular tachyarrhyth-
mia, severe left ventricular outflow tract obstruction and cardiogenic shock are more serious 
manifestations of this syndrome. Non-specific symptoms such as weakness, cough and fever 
have also been reported [32–34].
9. Diagnosis
9.1. Laboratory investigations
The measurement of cardiac enzymes such as serum troponin and creatinine kinase is essential 
to the diagnosis of the Takotsubo syndrome. Although, cardiac troponin levels are elevated in 
most patients with TTS, the rise in its levels is disproportionately low relative to the extent of 
regional wall-motion abnormality and cardiac dysfunction [24, 35]. In contrast, elevated values 
of cardiac natriuretic peptides, such as pro-BNP and NT-proBNP, serve as a better correlate 
for degree of ventricular wall dysfunction in the acute phase of TTS [36–38]. Normal values 
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of NT-proBNP are extremely rare in Takotsubo syndrome, thus helping it serve as a valuable 
marker of myocardial deterioration and recovery.
Recent studies have suggested the potential of circulating microRNAs to differentiate between 
TTS and STEMI patients; however, conclusive research is needed to establish this as a routine 
diagnostic biomarker [39].
9.2. Electrocardiography
The acute phase of TTS is characterised by ECG abnormalities such as ST-segment elevation, 
ST-segment depression, new left bundle branch block, Q-waves, T-wave inversions and signif-
icant QT-interval prolongation developing 24–48 hours after onset. These changes are reflected 
in almost 95% of all patients diagnosed with the Takotsubo syndrome [40]. It is not uncommon 
for the QTc-interval to be prolonged more than 500 ms, predisposing the patient to torsades de 
pointes and ventricular fibrillation, see Figure 1.
9.3. Echocardiography
The initial assessment of LV morphology and function with the use of thoracic echocardiog-
raphy is inherent to the diagnostic cascade of Takotsubo syndrome. Standard, colour and 
tissue Doppler techniques assist in the identification of anatomical variants, monitor recovery 
and help detect potential complications such as left ventricular outflow tract obstructions, RV 
involvement, mitral regurgitation and cardiac rupture [41–43].
The echocardiographic examination of patient in the acute phase of TTS shows a large area of 
poorly functioning myocardium extending beyond the territory of a single coronary artery. 
Figure 1. Electrocardiogram of TTS patient with acquired long QT syndrome at admission.
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The typical regional wall-motion abnormality is found in the apical to mid segments of the left 
ventricle, extending equally into the anterior, inferior and lateral walls. This ‘circumferential 
pattern’ is considered the hallmark of TTS. In certain cases, the use of a contrast agent for LV 
opacification eases assessment of the RWMA, while, myocardial deformation imaging with 
the speckle tracking method has been used to demonstrate a transient circular impairment 
of not only longitudinal LV function, but also circumferential and radial LV function [44–46].
9.4. Cardiac magnetic resonance
The use of cardiac magnetic resonance imaging (CMR) has been advocated in the first 7 days 
(acute phase) to accurately assess both LV and RV regional function and demonstrate the 
typical patterns of RWMA, permitted by the full visualisation of the ventricles in the main 
long axes. Cardiac magnetic resonance imaging has a distinct advantage over standard trans-
thoracic echocardiography in offering better views of the right ventricle and in detection of 
apical LV thrombi [47].
In CMR, tissue characterisation of acute myocardial changes occurring in the TTS patient 
shows a high signal intensity with a diffuse or transmural distribution, indicative of oedema 
of the hypokinetic LV myocardium. This oedema corresponds to the region of the wall-motion 
abnormality and is not restricted by the boundaries of a single coronary artery territory, 
unlike an acute myocardial infraction in which oedema is always coherent with a vascular 
distribution [42].
Late Gadolinium Enhancement (LGE) is typically absent in both the acute phase as well as 
follow-up, serving as an important criterion to distinguish between AMI and TTS. Recently, 
there has been some debate concerning the presence of minor LGE in the acute phase; how-
ever, this is dependent on the threshold of signal intensity used to define LGE presence [48, 
49], see Figure 2.
Figure 2. Magnetic resonance tomogram of patient with biventricular TTS showing a left ventricular thrombus formation 
as a related complication to TTS.
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9.5. Coronary angiography and left ventriculography
The necessity to exclude an acute myocardial infarction in patients presenting with angina-
like symptoms and typical ECG-changes predicates the use of coronary angiography. In TTS, 
the epicardial coronary arteries typically do not have any significant stenoses; however, there 
is possibility of bystander CAD considering the older age group of the presenting patients. 
A co-existing CAD has been reported in almost 10% of all TTS cases [50, 51]. The coronary 
stenosis in this scenario may or may not be hemodynamically significant; however, it is gener-
ally insufficient to explain the acute LV dysfunction and regional wall-motion abnormalities 
transpiring in the Takotsubo syndrome.
The exclusion of occlusive coronary artery disease, acute plaque rupture, thrombus forma-
tion and coronary dissection should be followed by a left ventriculography (if not contraindi-
cated). This is necessary to confirm the pattern of LV wall-motion abnormality and diagnose, 
if any, mitral regurgitation. It also allows direct measurement of the pressure gradient across 
the LVOT [42], see Figure 3.
9.6. Coronary computed tomography angiography
The role of coronary computed tomography angiography (CCTA) is limited to cases where 
a delay in access to urgent invasive coronary angiography is expected. Information acquired 
throughout the cardiac cycle (spiral or helical acquisition mode) during the acute phase could 
demonstrate the typical pattern of systolic dysfunction [52]; however, this would come at the 
cost of greater radiation exposure. Retrospective evaluation of patients with typical history of 
TTS could also theoretically include CCTA to exclude significant coronary stenosis.
9.7. Radionuclide imaging
Single-photon emission tomography (SPECT) with 201Thallium or 99mTechnetium-labelled radio-
pharmaceuticals and 123I-metaIodobenzyl-guanidine (mIBG) has been used to demonstrate 
Figure 3. Laevocardiography of TTS patient with typical apical ballooning triggered by emotional stress.
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myocardial perfusion and sympathetic innervation. A reduced mIBG in the dysfunctional myo-
cardial segments during the acute phase is consistent with disturbances in regional sympathetic 
neuronal activity [53, 54], and its use in diagnosing TTS has been suggested in combination with 
myocardial perfusion scintigraphy to exclude infarction.
18F-fluorodeoxyglucose (FDG) has been used to study myocardial glucose metabolism by 
positron emission tomography (PET); however, its current use has been relegated to scientific 
research [55].
10. Clinical management and therapeutic strategies
The clinical management protocol for Takotsubo syndrome is poorly defined as the debate 
explaining its pathophysiological evolution is yet to be resolved. As most patients present ini-
tially with symptoms of angina pectoris, it has been recommended that the first line of man-
agement be directed towards the treatment of possible myocardial ischemia. This essentially 
entails treatment with anticoagulants such as aspirin and heparin. Once occlusive coronary 
artery disease has been excluded, the objective of treatment is to minimise complications and 
ensure optimal supportive care. Patients are usually admitted to the coronary care unit to 
enable seamless continuous ECG-monitoring, serial lab tests and repeated echocardiographic 
examinations.
Takotsubo patients constituting a low-risk profile, with insignificant compromise to cardiac 
function (LVEF > 45%) could be discharged from the hospital early, however, only after a 
thorough review of the cardiovascular risk factors and heart failure medication. Recent pre-
clinical trials have advocated therapy with beta-blockers such as metoprolol and carvedilol in 
patients with low-risk [26, 56], unless contraindications to use pre-exist.
Interesting observations in this regard are the results published from a study by Templin 
et al., where the use of angiotensin-converting enzyme-inhibitors or angiotensin-receptor-
blockers, and not beta-blockers, were associated with improved survival [9].
In patients presenting with severely depressed cardiac output and complications associated 
with the Takotsubo syndrome, it is advised to stop drugs with sympathomimetic properties 
(e.g. catecholamines and beta-2-agonists). A therapy with beta-blockers has been recom-
mended in hemodynamically stable patients with atrial and ventricular tachyarrhythmias 
[10], as also in patients with a hemodynamically significant LVOT obstruction (in combi-
nation with an alpha-1-recpetor agonist). In severe manifestations like acute cardiogenic 
shock, options like use of temporary left ventricular assist devices and extracorporeal mem-
brane oxygenation could be considered. The potential of IABP in this scenario has taken a 
backseat considering the neutral data presented in the recently concluded IABP-SHOCK II 
Trial.
The use of inotropes, like norepinephrine or dobutamine, is mostly contraindicated in the 
Takotsubo syndrome; however, experts have recommended treatment with Levosimendan 
in patients with advancing cardiogenic shock and multi-organ failure [57–61]. The role of 
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prophylactic anticoagulation with unfractionated or low-molecular weight heparin is also 
 debatable, but experts have suggested that TTS patients with extensive segmental akinesia 
could be started on a regimen with therapeutic doses of LMWH.
11. Complications
Takotsubo syndrome has been associated with a growing list of complications of varied sever-
ity, contributing to its mortality rate. Almost 52% of all patients have been reported to develop 
some form of complication in course of this disease [62, 63]. These include acute heart failure, 
left ventricular outflow tract obstruction, cardiogenic shock, arrhythmias, thrombus forma-
tion, pericardial effusion, right ventricular involvement and ventricular wall rupture.
Acute heart failure develops in almost 12–45% of all patients with TTS and, in some patients, 
it is exacerbated by mitral regurgitation and/or left ventricular tract obstruction. Patients 
could have significantly elevated LVOT gradients (20–140 mmHg), and those with values 
greater than 40 mmHg are predisposed to develop hypotension and cardiogenic shock. It has 
been demonstrated that the use of inotropic drugs exacerbates this LVOT obstruction, while 
beta-blockers decrease it. Around 4–20% of all TTS patients show symptoms of cardiogenic 
shock, while almost 9% of them document ventricular arrhythmias during the acute phase. 
Thrombi develop generally 2–5 days after the index event and are known to resolve after 2 
weeks of therapeutic anticoagulation (treatment regimen of at least 3 months). There are also 
instances of patients presenting with a biventricular involvement, which has been associated 
with a poorer prognosis and a higher frequency of heart failure [10].
12. Prognosis and conclusion
The Takotsubo syndrome is essentially a benign disease and the prognosis is favourable in 
most patients. The regional wall-motion abnormalities usually resolve spontaneously within 
a few days to weeks; however, there have been instances where TTS has persisted due to 
complications associated with apical thrombus formation [64, 65]. Recent studies have dem-
onstrated that the in-hospital death rate ranges between 0 and 8%, while recurrence rates 
fluctuate anywhere between 0 and 15% [66, 67].
These results have eschewed renewed interest into the study of Takotsubo syndrome and 
mechanisms contributing to its pathophysiology. Patients are now recommended routine 
follow-ups after 3–6 months to evaluate the progress of disease and help better understand its 
evolutionary dynamics.
Limited current knowledge and often contradictory data have fuelled the debate surrounding 
the Takotsubo syndrome. There is an urgent need for multiple randomised controlled trials 
and large registries to optimise existing clinical goals and management strategies, and the 
launch of InterTAK registry is a step forward in this regard.
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